Johnson & Johnson Announces $55 Billion Investment in U.S. Pharma and MedTech Operations Over Next Four Years

Johnson & Johnson recently announced that it will invest more than $55 billion in its U.S. pharmaceutical and medical technology business sectors over the next four years.For manufacturing, R&D, and technology infrastructure construction. This investment scale has increased by 25% compared to the previous four years, marking another leap forward from the already high investment levels driven by the 2017 Tax Cuts and Jobs Act.

Executive Evaluation

"Today's announcement accelerates the fulfillment of our nearly 140-year commitment as an innovation engine in the United States — dedicated to tackling the world's toughest healthcare challenges. By choosing to establish a high-tech production base in North Carolina as the starting point of this investment, we will not only create more local job opportunities but also produce cutting-edge therapeutic drugs for patients in the U.S. and around the globe."

---Joaquin Duato Chairman of the Board and Chief Executive Officer of Johnson & Johnson

In addition to the new construction project in Wilson, North Carolina, Johnson & Johnson's investment plan this round includes:

• Build Three Advanced Manufacturing Bases and Expand Existing Facilities: Covering innovative drug and medical technology business sectors, creating high-paying high-tech jobs (specific location to be announced later)

• Strengthen R&D Infrastructure: Focusing on the key areas of oncology, neuroscience, immunology, cardiovascular diseases, and robotic surgery, accelerating the development of transformative therapies.

• Upgrade Technology Investment: Accelerate the drug discovery process through technological innovation, enhance employee training, and optimize operational systems.

This round of investment will further expand Johnson & Johnson's contribution to the U.S. economy. The company currently has an annual economic impact of over 100 billion U.S. dollars in the United States, and the new investment will continue to increase this figure.

Yesterday, the groundbreaking ceremony for the production base in Wilson, North Carolina, marked the beginning of a new chapter in investment.ProductionThe base covers an area of 500,000 square feet, with a total investment of approximately 2 billion US dollars, and will be constructed as a cutting-edge biologics production base. The new base will offer the following three benefits:

• Enhance the Global Supply Capacity of Next-Generation Therapies for Cancer, Immune-Mediated Diseases, and Neurological Disorders

• Create approximately 5,000 jobs during the construction phase and add 500 long-term positions after production begins.

• Expected to Create $3 Billion Economic Value for North Carolina in the First Ten Years of Operation

FollowAs Trump took office, the return of manufacturing becameKey Focus of the Trump Administration, Also Becoming the Main Theme for European and American Companies, Thus Major Global Medical Companies Announce Return to the U.S. Besides Johnson & Johnson, Companies Like Novo Nordisk, Eli Lilly,AstraZeneca,BD and other major manufacturers have announced increased investments in the United States.

• Novo Nordisk Invests $4.1 Billion in Building a Plant in North Carolina;

• Lilly to Double Investment in the U.S., Cumulative Total Exceeds $50 Billion Since 2020;

• AstraZeneca to Boost Manufacturing and R&D Capabilities by 2026, Adding $2 Billion to Its Investment in the U.S.;

• BD Plans to Increase Local Production Capacity of Safety Injection Devices by Over 40% and Traditional Syringes by More Than 50%.